Pfizer kidney cancer drug fails as initial treatment
(Reuters) - Pfizer Inc said its kidney cancer drug did not meet the main goal of showing a statistically significant improvement in survival in a late-stage trial without the cancer getting worse.
The trial was testing the drug Inlyta in patients who have received no prior treatments and compared its effects with another kidney cancer drug, sorafenib. Inlyta is already approved to treat kidney cancer that has not responded to prior therapy.
Sorafenib is marketed as Nexavar by Onyx Pharmaceuticals Inc and Germany's Bayer AG. (Reporting by Esha Dey in Bangalore; Editing by Sreejiraj Eluvangal)
- Tweet this
- Share this
- Digg this
- Hurricane-force winds wreak havoc in Britain, head to Europe
- Mexico hospitalizes six suspected of stealing radioactive material
- Aide to North Korean leader's ousted uncle seeks asylum in South - media
- China Rongsheng ghost town reflects shipbuilder's struggle to survive
- U.N., U.S. call for investigations into Thai trafficking of Rohingya